Literature DB >> 8846657

The role of bisphosphonates in the prevention and treatment of osteoporosis.

J Y Reginster1.   

Abstract

The first-generation biphosphonate etidronate is used only experimentally in osteoporosis prevention. Its effects in treating osteoporosis have been studied only in subjects who already have vertebral crush fractures. No reduction in the incidence of fractures in this population as a whole has been established. The suggestion of a more pronounced beneficial effect seen in severely osteoporotic patients treated with bisphosphonates for two years that seems to emerge from a posteriori analysis must be confirmed. The long-term safety of this therapy is currently under study. Subsequent generations of bisphosphonates are still experimental, whether for prevention or treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846657     DOI: 10.1007/bf02210684

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

Review 1.  Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.

Authors:  J Y Reginster
Journal:  Bone       Date:  1992       Impact factor: 4.398

2.  Prevention of postmenopausal bone loss by tiludronate.

Authors:  J Y Reginster; M P Lecart; R Deroisy; N Sarlet; D Denis; D Ethgen; J Collette; P Franchimont
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

3.  Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.

Authors:  R Pacifici; C McMurtry; I Vered; R Rupich; L V Avioli
Journal:  J Clin Endocrinol Metab       Date:  1988-04       Impact factor: 5.958

4.  Preliminary observations of a form of coherence therapy for osteoporosis.

Authors:  C Anderson; R D Cape; R G Crilly; A B Hodsman; B M Wolfe
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

5.  Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats.

Authors:  T J Wronski; C F Yen; K S Scott
Journal:  J Bone Miner Res       Date:  1991-04       Impact factor: 6.741

6.  Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis.

Authors:  M Passeri; M C Baroni; M Pedrazzoni; G Pioli; M Barbagallo; D Costi; M Biondi; G Girasole; B Arlunno; E Palummeri
Journal:  Bone Miner       Date:  1991-12

7.  Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover.

Authors:  R D Hesch; J Heck; G Delling; E Keck; J Reeve; H Canzler; O Schober; H Harms; E F Rittinghaus
Journal:  Klin Wochenschr       Date:  1988-10-03

8.  Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study.

Authors:  A B Hodsman
Journal:  Bone Miner       Date:  1989-01

9.  Effect of etidronate disodium on bone turnover following surgical menopause.

Authors:  M L Smith; I Fogelman; D M Hart; E Scott; J Bevan; I Leggate
Journal:  Calcif Tissue Int       Date:  1989-02       Impact factor: 4.333

10.  Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats.

Authors:  B C Toolan; M Shea; E R Myers; R E Borchers; J G Seedor; H Quartuccio; G Rodan; W C Hayes
Journal:  J Bone Miner Res       Date:  1992-12       Impact factor: 6.741

View more
  1 in total

1.  Icariin prevents bone loss by inhibiting bone resorption and stabilizing bone biological apatite in a hindlimb suspension rodent model.

Authors:  Jin-Peng He; Xiu Feng; Ju-Fang Wang; Wen-Gui Shi; He Li; Sergei Danilchenko; Aleksei Kalinkevich; Mykhailo Zhovner
Journal:  Acta Pharmacol Sin       Date:  2018-06-11       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.